Safety and Efficacy of Intravenous IDOV-Immune in Patients With Advanced Solid Tumors

NCT07656090 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ENROLLING_BY_INVITATION

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Cancer

Interventions

BIOLOGICAL: Oncolytic Virus injection(IDOV-Immune)

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences